Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367125 | 0.87 | FAAH (0.38) | OPRM1OPRL1GAAFAAHMGLL | |
| SCHEMBL6633133 | 0.77 | SIGMAR1 (0.47) | OPRL1MC4RFAAHCYP2D6CYP3A4 | |
| SCHEMBL15099421 | 0.76 | KMT2A (0.40) | FAAHCYP2D6CYP3A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL15093833 | 0.75 | KMT2A (0.39) | FAAHCYP2D6CYP3A4MEN1KMT2A | |
| SCHEMBL15099391 | 0.74 | MC4R (0.47) | OPRM1OPRL1MC4RGAADRD4 | |
| SCHEMBL24394468 | 0.71 | JAK3 (0.49) | OPRM1MC4RDRD4CYP2D6CYP3A4 | |
| SCHEMBL15478093 | 0.71 | HCRTR1 (0.51) | MC4RGAAMEN1KMT2ASIGMAR1 | |
| SCHEMBL4319672 | 0.69 | OPRM1 (0.37) | OPRM1OPRL1ELANECTSGPRTN3 | |
| SCHEMBL8330597 | 0.68 | MC4R (0.61) | OPRL1MC4RCYP2D6CYP3A4MEN1 | |
| SCHEMBL18712903 | 0.68 | CYP2D6 (0.60) | MC4RGAACYP2D6CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| WO-2013102242-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | OPRM1 99/4885OPRL1 8/4885MC4R 610/4885 |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | OPRM1 102/4885OPRL1 8/4885MC4R 615/4885 |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | OPRM1 102/4885OPRL1 8/4885MC4R 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.